Early Interventions to Reduce the Impact of Immunogenicity on the Development of Biopharmaceuticals

The development of biological therapeutics such as humanised antibodies has led to remarkable clinical benefits in many indications. Despite this success, the induction of anti-drug antibodies (ADAs), due to the potential immunogenicity of these therapeutics, remains a significant challenge to the successful development of biotherapeutics. This article looks at the impact of immunogenicity and approaches that can be taken in pre-clinical development to reduce the impact on product success and patient experience.

Please enter your details to access this peer-reviewed article.